Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 5/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719608 | 0.94 | RAB9A (0.54) | EPHX2ALDH1A1PTAFRTBXAS1MEN1 | |
| SCHEMBL7724191 | 0.89 | KDM4E (0.50) | EPHX2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7723854 | 0.88 | CYP1A2 (0.59) | ALDH1A1RAB9AKMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL7729374 | 0.85 | EPHX2 (0.54) | EPHX2ALDH1A1PTAFRTBXAS1MEN1 | |
| SCHEMBL7723042 | 0.84 | SMN1; SMN2 (0.51) | EPHX2NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL7719685 | 0.83 | KDM4E (0.42) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7724193 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7723067 | 0.82 | HPGD (0.46) | EPHX2NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL7723054 | 0.79 | RAB9A (0.51) | EPHX2ALDH1A1PTAFRTBXAS1MEN1 | |
| SCHEMBL2841099 | 0.78 | EPHX2 (0.65) | EPHX2ALDH1A1PTAFRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | EPHX2 1074/4885ALDH1A1 988/4885PTAFR 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.